Breaking News

SK bioscience Establishes Songdo Research & Process Development Center

SK bioscience plans to operate the Open Lab in the R&PD Center to strengthen a global vaccine network.

SK bioscience, a global vaccine and biotech company that promotes human health from prevention to cure across the globe, has established the Songdo Global Research & Process Development Center (The R&PD Center), in Songdo, Korea. The R&PD Center is scheduled to be completed in the first half of 2025. The company is investing $261 million, that includes a previous investment of $33 million. Jaeyong Ahn, CEO of SK bioscience said, “The establishment of the R&PD Cente...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters